Associate Professor in Paediatrics and Vaccinology
- BRC Consultant in Paediatrics and Vaccinology
Matthew Snape, MBBS FRCPCH MD, is an Associate Professor in General Paediatrics and Vaccinology at the Oxford Vaccine Group, University of Oxford Department of Paediatrics and the NIHR Oxford Biomedical Research Council. He is also a Jenner Investigator, an Academic Training Programme Director and works as a General Paediatrician at the Children’s Hospital Oxford, Oxford University Hospitals NHS Trust.
Assoc. Prof. Snape's principal areas of research relate to vaccines against meningococcal, pneumococcal, influenza, RSV and Ebola virus disease. In 2014/2015 he was the lead investigator on a 'first in human' phase 1 study of a candidate ebola vaccine, providing data crucial to the planning of subsequent studies in West Africa. He is currently the Chief Investigator of the 'Be on the TEAM' study enrolling 24 000 Year 12 students to evaluate the impact of immunisation with group B meningococcal vaccines on pharnygeal carriage of meningococcus, and is the Director of the National Immunisation Schedule Evaluation Consortium (NISEC), both of which are NIHR funded. Other projects include leading on the instigation of the Global Platform for Prevention of Autoimmune Diabetes (GPPAD) in the UK and acting as a Chief or Principal Investigator on clinical trials of multiple RSV vaccine candidates.
Assoc. Prof. Snape graduated from the University of Melbourne in 1993 and completed his basic paediatric training at the Royal Children’s Hospital, Melbourne before continuing his training at St Mary’s Hospital, London. While working in the Paediatric Intensive Care Unit at St Mary’s hospital he became interested in the prevention of invasive meningococcal disease by immunisation, and on completion of his clinical training took up a post as a research fellow (later Clinical Lecturer) at the Oxford Vaccine Group, University of Oxford. While here he completed his post- graduate Doctor of Medicine (MD) degree, awarded by the University of Melbourne in 2009. He has been employed as a Consultant in General Paediatrics and Vaccinology since 2009 and was appointed an Associate Professor in 2018.
Assoc. Prof. Snape was acknowledged as an NIHR Clinical Research Network ‘Leading Commercial Principal Investigator’ in 2015 by Dame Sally Davis, Chief Medical Office, an exceptional Principal Investigator by the Thames Valley Clinical Research Network in 2016 and received a Vice Chancellor's award for Public Engagement in Research in 2016. He has published over 100 manuscripts relating to immunisation and is a member of the Meningitis Research Foundation's Medical Advisory Group.
Assoc. Prof. Snape is an Academic Training Programme Director for Oxford University Clinical Academic Graduate School (OUCAGS), with a particular focus on paediatric academic training.
Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol.
Ziegler A-G. et al, (2019), BMJ Open, 9
Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials-GPPAD-02 study design and first results.
Winkler C. et al, (2019), Pediatr Diabetes
Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization
O'Connor D. et al, (2019), Cell Reports
Determinants of Influenza and Pertussis Vaccination Uptake in Pregnancy: A Multicenter Questionnaire Study of Pregnant Women and Healthcare Professionals.
Wilcox CR. et al, (2019), Pediatr Infect Dis J, 38, 625 - 630
Persistent circulation of vaccine serotypes and serotype replacement after five years of UK infant immunisation with PCV13
Kandasamy R. et al, (2019), Journal of Infectious Diseases